A higher proportion of patients who continued to the third line tended to have hypertension, peripheral neuropathy, or hand–foot syndrome compared with patients who transitioned to the BSC, indicating potential side effects from longer durations of previous lines of OX, IRI, and VEGF inhibitors and/or anti-EGFR antibodies. The gene discussed is VEGFA; the disease is Hypertension.